Trial Profile
Phase II study of bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cisplatin (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 21 Jan 2022 This trial has been completed in Slovenia, according to European Clinical Trials Database record. (20 Jan 2012)
- 14 Jan 2013 Planned end date changed from 1 Dec 2009 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 11 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.